-
公开(公告)号：US11747335B2
公开(公告)日：2023-09-05
申请号：US16668397
申请日：2019-10-30
发明人： David Schneider
IPC分类号： G01N33/53 , G01N33/569 , G01N33/86 , G01N33/68 , A61K31/4365 , A61K31/443 , A61K31/519
CPC分类号： G01N33/56966 , A61K31/4365 , A61K31/443 , A61K31/519 , G01N33/6854 , G01N33/86 , G01N2333/70535 , G01N2800/222 , G01N2800/226 , G01N2800/52
摘要： Compositions and methods are provided for determining platelet reactivity where the levels of FcγRIIa on the surface of platelets is measured and if the levels of FcγRIIa are greater than a reference value, the platelets have enhanced reactivity.
-
公开(公告)号：US20230096313A1
公开(公告)日：2023-03-30
申请号：US17945709
申请日：2022-09-15
申请人： Uni Pharma Co., LTD.
发明人： Yu-Shan Wang
IPC分类号： G01N33/86 , G01N1/40 , G01N33/574 , G01N33/543
摘要： Two methods for quantifying fibrin/fibrinogen degradation products (“FDP”) in a blood sample. The first method features obtaining a blood sample from a non-human animal, centrifuging the blood sample to obtain a first supernatant and collecting the first supernatant, centrifuging the first supernatant to obtain a second supernatant and collecting the second supernatant, diluting the second supernatant, contacting the diluted second supernatant with a reagent that contains antibodies specifically binding to FDP, and detecting an amount of antibodies specifically bound to FDP, thereby quantifying FDP in the blood sample. The second method requires subjecting the diluted second supernatant to a quantitative immunoassay that specifically detects FDP to quantify the amount of FDP in the non-human blood sample.
-
公开(公告)号：US20230048418A1
公开(公告)日：2023-02-16
申请号：US17934454
申请日：2022-09-22
摘要： The invention relates to the diagnosis of stroke resulting from occlusion of one or more large vessels in the brain, and in particular to the diagnosis of stroke resulting from occlusion of one or more large vessels in the brain using one or more biomarkers.
-
公开(公告)号：US20230009208A1
公开(公告)日：2023-01-12
申请号：US17848523
申请日：2022-06-24
申请人： The Brigham and Women’s Hospital, Inc. , President and Fellows of Harvard College , Vilnius University
摘要： A system and method are provided for harvesting target biological substances. The system includes a substrate and a first and second channel formed in the substrate. The channels longitudinally extending substantially parallel to each other. A series of gaps extend from the first channel to the second channel to create a fluid communication path passing between a series of columns with the columns being longitudinally separated by a predetermined separation distance. The system also includes a first source configured to selectively introduce into the first channel a first biological composition at a first channel flow rate and a second source configured to selectively introduce into the second channel a second biological composition at a second channel flow rate. The sources are configured to create a differential between the first and second channel flow rates to generate physiological shear rates along the second channel that are bounded within a predetermined range.
-
公开(公告)号：US11519917B2
公开(公告)日：2022-12-06
申请号：US16604269
申请日：2018-04-13
申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN , THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
发明人： James H. Morrissey , Stephanie A. Smith , Catherine J. Baker , Rachel Hemp , Richard J. Travers
摘要： Provided herein are compositions and methods for quantifying polyphosphates. In particular, provided herein are solution and substrate based assays for quantifying polyphosphates in complex samples.
-
公开(公告)号：US11519914B2
公开(公告)日：2022-12-06
申请号：US16480342
申请日：2018-01-25
发明人： Esther Rabizadeh
IPC分类号： G01N33/86 , G01N33/574
摘要： A method for diagnosing a malignant proliferative disease or disorder in a subject, and/or for following up, monitoring or prognosticating the therapy of a malignant proliferative disease or disorder in a subject is disclosed. The method is based on measurement of platelet-mediated fibrinogen-like protein 2 (FGL2) activity in a sample essentially comprising platelets obtained from the subject. In accordance with the disclosed method, platelet-mediated FGL2 activity level higher than control is indicative of the presence of a malignant proliferative disease or disorder in a subject.
-
公开(公告)号：US20220373566A1
公开(公告)日：2022-11-24
申请号：US17767143
申请日：2019-10-17
发明人： Mary Pomeroy , Martina Medkova , Jeff Chien
摘要： This invention relates to a method and apparatus for determining the activity of coagulation factors in dilute capillary whole blood, citrated whole blood and citrated plasma. It also includes the detection of the hemoglobin amount in a whole blood sample so a correction of the clotting time can be performed thereby making the clotting time values independent of hemoglobin and hematocrit effect.
-
公开(公告)号：US20220373565A1
公开(公告)日：2022-11-24
申请号：US17620436
申请日：2020-06-19
发明人： Toshiki KAWABE , Yukio ODA , Midori SHIMA , Keiji NOGAMI , Kenichi OGIWARA , Naruto SHIMONISHI
摘要： An APTT prolongation factor estimation system includes one or more facilities each including an analyzer which measures a blood coagulation reaction of a subject blood specimen, a database which stores data on a blood coagulation reaction and APTT prolongation factor of blood specimens, and a computer which estimates an APTT prolongation factor of the subject blood specimen based on the data on the blood coagulation reaction from the analyzer and the data stored in the database. The facilities each further includes a data transmission unit which transmits, to the computer, the data on the blood coagulation reaction of the subject blood specimen obtained by the analyzer, and a data reception unit which receives a result of the estimation of the APTT prolongation factor, which is obtained by the computer, regarding the subject blood specimen measured by each of the analyzers.
-
公开(公告)号：US20220243250A1
公开(公告)日：2022-08-04
申请号：US17720577
申请日：2022-04-14
发明人： Andrea Lichte , Michael-Harold Town
摘要： A method for determining a non-anticoagulant interferent in a blood-derived sample of a subject, the method comprising a) determining a value of a coagulation time-related parameter in the sample; b) comparing the value of the coagulation time-related parameter determined in a) to a value of the coagulation time-related parameter determined in at least one reference sample; and c) based on the result of comparison step b), determining the non-anticoagulant interferent in a blood-derived sample of a subject. A method for identifying a blood-derived sample having insufficient quality is further disclosed, the method comprising determining non-anticoagulant interferent(s) according to the aforesaid method.
-
公开(公告)号：US11372008B2
公开(公告)日：2022-06-28
申请号：US15979349
申请日：2018-05-14
发明人： Jurg Sommer
摘要： The present disclosure provides methods and compositions for diagnosing and treating subject having a bleeding disorder. The disclosed methods comprise contacting a sample, e.g., a blood or plasma sample obtained from the patient, with an activation mixture comprising an activated coagulation factor and a phospholipid mixture, wherein the activation mixture is dried onto a solid substrate. Also provided is a global hemostasis test based on the integration of clotting time (Ct) and pharmacokinetics data. The methods and compositions presented can be applied to point-of-care diagnostic systems.
-
-
-
-
-
-
-
-
-
搜索结果
1887 条记录 (耗时 0.031 秒)
